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Objetive: Study the difference in expression of specific microRNAs in hypoxia and DNA 
damage response in breast cancer stem cells after receiving radiation doses versus a control 
that has not been radiated. 
 
Methods: Breast adenocarcinoma cell line MDA-MB-231 was choosing for the study. CSCs 
of MDA-MB-231 isolation were performed by detecting activity of ALDH by flow 
cytometry, obtaining population positive (sorter+) and population negative (sorter-). Then 
cultivate these populations in spheres culture medium including general population (no 
sorter). After 72h cells were radiated by different doses and incubated 24h for later isolation 
RNA. To study the expression of two selected miRNAs was carried out a RT-qPCR. 
 
Results: miRNAs examined were as follows: Hsa-mir 210 and Hsa-mir 24 together control 
GADPH standardized. When no sorter cells are radiated with 2 Gy the expression of mir 210 
was 0,41 versus control when they are radiated with 6 Gy observed was 3,23. The expression 
of mir 210 in sorter+ was 91,40 in non-radiated cell, while when were radiated to 2 Gy and 6 
Gy was 26,42 y 10,88 respectively. The expression of mir 24 in no sorter cells was 1,49 and 
0,31 when were radiated to 2 Gy and 6 Gy decreases to 0,31 respectively. mir 24 expression 
in sorter+ non-radiated was 3,08, for 2Gy was 1,11 and for 6 Gy was 0,87.  
 
Conclusions: Ionizing radiation affects the expression levels of miR 210 and miR 24 both in 
non-sorted population as in ALDH+ BCSCs. Ionizing radiation decreases miR 210 and miR 































































 Breast cancer is the second most common cancer in the world and, by far, the most 
frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 
2012 (25% of all cancers). It is the most common cancer in women both in more and less 
developed regions with slightly more cases in less developed (883,000 cases) than in more 
developed (794,000) regions. Incidence rates vary nearly four-fold across the world regions, 
with rates ranging from 27 per 100,000 in Middle Africa and Eastern Asia to 96 in Western 
Europe (GLOBOCAN). 
 
 Breast cancer ranks as the fifth cause of death from cancer overall (522,000 deaths) 
and while it is the most frequent cause of cancer death in women in less developed regions 
(324,000 deaths, 14.3% of total), it is now the second cause of cancer death in more 
developed regions (198,000 deaths, 15.4%) after lung cancer. The range in mortality rates 
between world regions is less than that for incidence because of the more favourable survival 
of breast cancer in (high-incidence) developed regions, with rates ranging from 6 per 100,000 
in Eastern Asia to 20 per 100,000 in Western Africa (GLOBOCAN). 
 
 In the province of Granada were reported, 19.634 cases corresponding to residents, in 
the period 2008-2011 first diagnosed with cancer during those years, representing an average 
of 4,908 new cases per year. In the period 2008-2011, the average annual incidence of breast 
cancer in Granada presented gross rates of 1 and 94 per 100,000 men and women, 
respectively (1 new case was diagnosed per 100,000 men and 94 new cases per 100,000 



















 Cancer is a disease that primarily affects older adults. In both genders, the specific 
cancer incidence rates are higher with increasing age, following a different pattern in men and 
women and produced an increase from the 50. 36% of cases of breast cancer occur in women 
in the age group 65 years and approximately half of the cases occur in women aged 45-64 
years (Table 1) (Registro del cancer de Granada). 
 
Relative frequency 




 2. Cancer stem cell (CSCs) 
 
 The stochastic cancer model postulates that one or more tissue cells acquire a mutation 
and through an uncontrolled division process, are new genetic alterations are accumulated 
leading the selection of the fittest clones. According to this model, any cell of the tumor 
would be able to maintain and expand the tumor as well as to give rise to new tumors. 
Conversely, the hierarchical model of the cancer stem cell (CSC) implies the existence of a 
source cell in the tumor stem cell properties, able to proliferate and maintain indefinitely the 
growth due to its self-renewing ability. In this model, only the population of CSC has the 
ability to generate and maintain tumor, unlike other cells that form do not have that ability 
(Figure 2) (Eguiara et al., 2012). 
 
Figure 2: Stochastic model and Cancer Stem model picture from (Sasha D Girouard and George 
F Murphy, 2011) 
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 Solid tumors similar to aberrantly developed organs and tissues are composed of many 
types of cells including neoplastic cells, supporting vascular cells, inflammatory cells, and 
fibroblasts. The majority of cells in bulk tumors have limited self-renewal ability and are non-
tumorigenic. Only a small subpopulation of cancer cells is long-lived with the ability of 
extensive self-renew and tumor formation. This small population is called cancer stem cells 
(CSCs), or cancer initiating cells (CICs), or tumor stem cells (TSCs) (Han et al, 2013). 
 The first strong in vivo evidence in support of the CSC concept came from classical 
implantation studies in human leukaemia by Bonnet and Dick in 1997. They used 
fluorescence-activated cell sorting (FACS) to isolate a specific cell population from acute 
myeloid leukaemia (AML) patients that were able to initiate AML following implantation 
into non-obese diabetic mice with severe combined immunodeficiency (NOD/SCID). The 
leukaemia-initiating cells were defined by expression of the cell surface antigen CD34 and 
displayed self- renewal, differentiative and proliferative capacities similar to normal 
haematopoietic stem cells. The first evidence for the existence of CSCs in solid human 
tumours came from studies in breast cancer (Figure 3)(Ablett et al., 2012). 
 
 The CSCs have the characteristics of stem cells such as the unlimited self-renewal 
capacity, proliferation and differentiation to different cell lines features. Among the highlights 
of the CSCs that make fundamental in the development of tumors can be found tumorigenic, 
drug resistance, radiotherapy resistance, recurrence and metastasis.  
 While CSC theory appears to be attractive, it has its own pitfalls. A number of 
molecular pathways have been proposed to play a role in maintenance of CSC phenotype 
which is further complicated by the observation that none of the molecular markers of CSCs 
seems to be universally relevant. Most of the research is cancer specific, and the 
factors/pathways relevant in one cancer may or may not be relevant targets for therapy in 






Figure 3: Markers used for the identification and isolation of cancer stem cells from different cancers 




 3. Breast cancer stem cell (BCSCs) 
 
 Al-Hajj and colleagues prospectively isolated a tumorigenic population of cells from 
primary human breast cancers using FACS based on the ESA+/ CD44+/CD24-low/lineage- 
phenotype. (Ablett et al., 2012). The CD44+/CD24- phenotype has been used extensively to 
identify and isolate cancer cells with increased tumorigenicity. In addition to cell surface 
markers, other expresión based methods of CSC enrichment have been developed. Aldehyde 
dehydrogenase (ALDH) activity has been identified as a method of enriching for normal 
human breast stem and CSCs. Furthermore, by combining ALDH activity with 
CD44highCD24− expression, the CSC fraction was refined further compared to either method 
alone. Interestingly, the ALDH−/CD44high/CD24− population was not enriched for CSCs 
demonstrating that the CD44highCD24− population retains significant heterogeneity (Figure 4) 
(Owens and Naylor, 2013). 
which is among the key regulators of stem cells from
various tissues and also plays a critical role in CSCs.
Inhibition of Hedgehog signaling suppressed CSC prolifer-
ation and self-renewal and increased apoptosis [57].
Importantly, it was reported that glioblastoma cells remain
viable after hedgehog blockade but are no longer ap ble of
tumor initiation, indicating that the hedgehog pathway is
required for maintaining the CSC population [58].
CSC niches
An additional similarity between CSCs and non-transformed
stem cells is their dependence on particular niches—
specialized microenvironments in which the surrounding
cells, extracellular matrix, and soluble factors are critical for
the maintenance of cell stemness. In situ, CSCs have been
found enriched in perivascular regions [59], and similar
findings have been reported for neural stem cells [60–62].
Recent studies have started to shed light on the signaling
mecha isms regulating CSCs in the pe ivascular niche.
Medulloblastoma CSCs localized in the vicinity of blood
vessels were resistant to radiation, owing to their ability to
activate the PI3K/Akt pathway and undergo a transient, p53-
dependent cell cycle arrest [63]. Intriguingly, the tumor
vasculature in gliomas expresses high levels of endothelial
nitric oxide synthase (eNOS). NO secreted from endothelial
cells can activate a cGMP/PKG dep ndent pathway leading
to enhanced Notch activity. This in turn leads to an increase
of the CSC pool and its self-renewal capacity [64].
Table 1 Markers used for the identification and isolation of cancer stem cells from different cancers
Cancer type CSC markers % of CSC cells in tumor Efficiency of tumor formationa
(transplanted cells)
Reference
Lung Sca-1+CD45–PECAM–CD34+ 0.008–0.064 ND [11]
CD133+ 0.3–22.0 ND [10]
Colon CD133 1.8–24.5 83% (500) [14, 15]
EpCAMhighCD44+ 0.03–38.0 (mean 5.4) 75% (200) [12]
ALDH1 3.5±1.0 ND (25) [13]
Breast CD44+EpCAM+CD24–Lineage– 0.6–5.0 100% (1,000) [19]
CD44+CD24-ALDH1+ 0.1–1.2 100% (20) [21]
Thy-1+CD24+CD45- 1.0–4.0 80% (50) [20]
Prostate CD44+!2"1
highCD133+ 0.1–0.3 ND [22]
Brain CD133 19–29 100% (100) [33]
CD15 5.6–70.5 100% (1,000) [34]
SP 0.15–1.2 ND [32]
Melanoma ABCB5 1.6–20.4 50% (100,000) [37]
Pancreatic CD44+CD24+EpCAM+ 0.2–0.8 50% (100) [24]
CD133 0.7–3.2 80% (500) [23]
Liver CD90+CD45– 0.7–6.2 50% (5000) [18]
Head and neck CD44 0.1–41.7 50% (5,000) [25]
Skin CD34 13.0–20.0 50% (1,000) [26]
Ovarian CD44+CD117+ 0.1–0.2 100% (100) [29]
CD133+ 0.3–35.0 (median 8.9) 83% (500) [28]
Bladder CD44 3.1–36.3 50% (1,000–3,000) [30]
Mesenchymal SP 0.07–10.5b 55% (100) [31]
Acute myeloid leukemia (AML) CD34++CD38– 0,02–2,00c 100%d (100,000–500,000) [8, 9]
Acute lymphoblastic
leukemia (ALL)
CD34+CD10–/CD34+CD19– 8±4/3±1c 100%d (50,000–200,000) [116]
a The efficiency represents the percentage of immunodeficient mice that form tumors following injection of the number of cells indicated in brackets
b Data presented only for a subset of tumors
c Percentage among mononuclear cells
d Percentage of engraftment
EpCAM epithelial cell adhesion molecule (also called epithelial-specific antigen), Lineage lineage markers: CD2, CD3, CD10, CD16, CD18,
CD31, CD64, and CD140b, SP side population




 Due to the intra and inter-tumor heterogeneity in cancer, it is possible that CSCs from 
different tumors have distinct expression profiles. Thus, isolating CSCs by function and 





Figure 4: Summary of preclinical, animal model and clinical evidence of breast cancer stem cell 




 4. Radioresistence 
 
 The CSC is thought to be directly responsible of the relapse in a tumor process after 
having received radiotherapy (RT). Radiation in vivo enriches the fraction of cells expressing 
CSC markers, which also have an enhanced self-renewal capacity and tumorigenicity 
compared to the tumor bulk. In addition, sorted CSC cells from different types of tumors 
survive such treatments in culture much better than unsorted or negative cells (Garvalov & 
Acker, 2010). 
 There are numerous studies on different tumor types, and CSC markers associated 
with them, supporting this hypothesis. It has been shown that CD133 positive cells, mostly 
associated brain cancer, are found in a greater proportion after receiving a fractionated 
radiation both in vitro and in vivo (Bao 2006). The population characterized as CD44+/ CD24-
low (breast cancer) is resistant to fractionated radiation treatment, keeping intact its capacity 
chemotherapy was 14-fold greater compared to cells
derived from chemotherapy naive patients.21 Further-
more mammospheres from chemotherapy treated
patients could be passaged up to 10 times, whereas the
self-renewal capacity of mammospheres from chemo-
therapy-naive patients became exhausted after three
passages. Importantly, by studying paired breast speci-
mens of seven patients before and after neo-adjuvant
chemotherapy the investigators demonstrated a signifi-
cantly greater mammosphere forming ability and a
9.5-fold increase in the proportion of CD44+/CD24!/low
cells after chemotherapy.21
A clinical study involving 31 patients by Li et al.
(2008) also demonstrated enrichment of putative br ast
CSCs following a 12 week course of neoadjuvant che-
motherapy with docetaxel or doxorubicin combined
with cyclophosphamide22 They showed that chemother-
apy increased the proportion of CD44+/CD24! cells by
3-fold and significantly increased the number of cells
able to generate mammospheres 4-fold. By establishing
human breast cancer xenografts from patients before
and after treatment they showed that chemotherapy
doubled tumour forming capacity in SCID/Beige mice
suggesting an enrichment of CSCs. Using a gene expres-
sion signature common to both CD44+/CD24!/low and
mammosphere forming cells, Creighton et al. (2009)
showed that these signatures were more pronounced in
tumour tissue from 12 patients following neoadjuvant
treatment with docetaxel.23 Together these studies sug-
gest that breast CSCs are relatively chemo-resistant,
and such therapy can enrich for this cell population.
Potential chemo-resistance mechanisms in CSCs include
increased expression of antiapoptotic proteins, increased
drug e!ux transporters and increased e"ciency of DNA
repair.24 Furthermore, it is possible that CSCs are less
sensitive to antimitotic agents due to a low rate of pro-
liferation. Chemotherapy may thus destroy non-CSCs in
a proportion of tumours, leaving the CSCs to poten-
tially re-seed disease.
4.2. Radio-resistance
Philips et al. (2006) demonstrated that mammo-
spheres derived from MCF-7 and MDA-MB-231 cell
lines were more radio-resistant than cells grown as
monolayer cultures.13 More importantly they demon-
strated that fractionated doses of irradiation increased
the proportion of tumour-initiating CD44+/CD24!/low
cells in the non-adherent cell populations of MCF-7
monolayer cultures. The authors proposed that reduced
induction of reactive oxygen species (ROS), reduced
double strand DNA breaks and induction of the
Notch-1 pathway were responsible for the observed rel-
ative radio-resistance of breast CSCs and greater
tumour re-growth during radiotherapy treatment gaps.
Similarly Diehn et al. (2009) proposed that CSCs
Table 2
Summary of preclinical, animal model and clinical evidence of breast cancer stem cell (CSC) resistance to chemotherapy, radiotherapy and
endocrine therapy.





ESA+CD44+/CD24low Cell lines 5-Flurouracil or Paclitaxel In vitro – FACS 5–30-fold " 5
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Mammosphere assay Cell lines Radiation – single & fractionated In vitro – clonogenic assay 2-
fold " in survival
13
CD44+/CD24!/low Cell lines Radiation – fractionated In vitro – FACS, up to 3-fold
"
104
Sca1+ BALB/c mice Mouse Radiation – single dose In vivo – FACS 3-fold " 26
CD24+Thy1+Lin! MMTV-
Wnt1
Mouse Radiation – fractionated In vivo – FACS, 2-fold " 25
Lin!CD29+CD24+ P53-
nullmouse












In vivo – 2-fold " in CK5
expression
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Neoadjuvant letrozol In vivo – " gene expression
signature
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for self-renew and being more aggressive and better able to reproduce the tumor and initiate 
metastasis (Phillips 2006, Lagadec 2010). Cells with high ALDH1 character a subpopulation 
with increased radioresistance, whose inhibition resulted in a sensitization to the same 
(Mihatsch 2011, Croker 2012).  
 
 The mechanisms by which CSCs may be resistant to RT can be framed into four 
groups: systems repair of DNA damage, redistribution of the cell cycle, cells tumor 
repopulation, and level of intratumor hypoxia (Figure 5).  
i) The ability to repair DNA lesions when CSCs did not reach the threshold to be lethal. 
Among different control points altered in this process allowing survival are such activation of 
ataxia telangiectasia mutated (ATM) in CD44+/CD24-/low cells (Yin 2011). Enrichment of 
polycomb group protein BMI1 in CD133 positive cells (Facchino 2010). The activation of the 
checkpoint kinases 1/2 which also leads to a survival of CD133 positive cells (Bao 2006). 
More evidence suggesting increased DNA damage repair capacity in CSCs came from the 
observation of γ-H2AX induction in BCSCs. γ-H2AX is the phosphorylated form of H2AX 
which is the gene encoding the histone H2A variant, H2AX. γ-H2AX is the sensitive 
surrogate of DNA double strain break, which can be quantified after radiation. It has been 
demonstrated by several groups that CSCs have lower γ-H2AX foci after radiation in human 
BCSCs. Wnt/β-catenin signaling pathway is a network of proteins essential in embryogenesis, 
stem cell maintenance and survival. More recently, this pathway has also been shown to be 
important in CSCs and their responses to DNA damages. One transcriptional target of β-
catenin is survivin which can promote survival in response to apoptotic stimuli. Survivin has 
been linked to radiation resistance and it has been demonstrated that suppression of survivin 
with a small molecule inhibitor may sensitize the radiation effects and induce more apoptosis 
(Chumsri, 2013). 
ii) Cell cycle phase distribution is important for sensibilisation to radiation. Cells in mitosis 
are more sensitive to radiation and those found in late S phase stronger, thus making a 
redistribution of the cell cycle resulting in a population in S phase. So if the radiation dose 
administered in the appropriate moment may act on the most sensitive stage making the 
treatment most effective (Pawlik 2005, Withers 1975).  
iii) Hypoxia is a fundamental pathophysiological phenomenon strongly associated with the 
development and aggressiveness of various solid malignancies and also implicated in 




so that the concentration thereof is controlled with great precision. An imbalance that results 
in a hyperoxia induces formation of reactive oxygen species (ROS) that can go causing cell 
death, and hypoxia can trigger the activation of pro-apoptotic pathways and pro-angiogenic 
(Brunner 2012). In the case of the ROS a study based on CD44 +/ CD24-/low cells. They were 
grown in suspension, a higher level of ROS was found compared to monolayer culture. After 
receiving a radiation dose an increase thereof in monolayer culture was shown but not in the 
suspension, which suggests that a large removal control of ROS lead to cell death avoidance 
caused by radiation (Phillips 2006). Cellular responses to hypoxia are commonly regulated by 
the hypoxia inducible factor (HIF). The higher level of HIF in the tumor can be correlated 
with the level of oxygen and it has been shown to correlate with the radiation resistance 
(Keith, 2007). There are two isoforms, HIF1a and HIF2a with differential expression in 
CD133 glioma cells, while HIF2a significantly was present in the CD133 positive population 
HIF1a was detected in the complete pool of cells, but was stabilized under conditions of 
hypoxia, and HIF2a overexpression way further related with poor prognosis (Li, 2009). 
 As tumors develop, the requirement for oxygen increases, leading to regions of 
hypoxia. Hypoxia causes activation of HIFs, which enable to cells to adapt to the low-oxygen 
environment. Hypoxic culture conditions (1% O2) induced an increase in the ALDH1+ 
proportion in breast cancer cell lines (Conley et al., 2012). Moreover, CSCs were enriched in 








Figure 5: CSCs evade radiation-induced cell death through the activation of survival pathways 




5.  Metalloproteinases (MMPs) 
 
 MMPs are a family of zinc-dependent endopeptidases secreted as zymogens by 
tumour and stromal cells. They play a crucial role during tumour invasion and metastasis 
through their ability to degrade matrix proteins and are also involved in early steps of 
mammary carcinogenesis (Chabottaux & Noel, 2007). ECM remodelling is controlled by 
MMPs and endogenous tissue inhibitors of MMPs (TIMPs). Interactions between TIMPs and 
MMPs are responsible for the regulation of MMP activity, and the increased production or 
activity of MMPs has very often been linked to malignancy. Hence, the balance between 
MMPs and TIMPs plays a crucial role in cancer progression and metastasis. Several studies 
have reported increased levels of different MMPs in diverse cancer tissues including breast 
tumours (Artacho-Cordón, 2012). 
capacity and reduced induction of apoptosis in response to irradi-
ation relative to the CD133! population [3]. These results suggest
that therapeutic targeting of the activation of DNA damage check-
points might provide a tool to sensitize CSCs to radiotherapy,
although targeting would need to be specific to the tumor cells
due to concerns for increased sensitivity of normal tissues.
It has been recently suggested that the use of particle beams of
protons and carbon ion may increase treatment efficiency towards
CSCs. Compared to photons, protons induce complex and clustered
DNA damage that is harder to repair [116,117]. Furthermore, the
level of DNA damage is less dependent of the presence of molecular
oxygen and the generati n of ROS [116,117]. A recently published
study on colorectal cancer aiming to compare the efficiency of X-
ray and particle beams showed hat treatment with carbon ion
was twice as effective in reducing the number of CSCs in vitro
and signific ntly r duced tumor growth [118]. Although these ini-
tial results are promising, further studies are necessary to confirm
these results.
Another aspect of the effects of radiation on tumor cells relates
to the possibility that it may induce the EMT process. Work re-
ported by Andarawewa et al. [119,120] has linked induced expres-
sion and activation of latent TGF-b by radiation to the induction of
EMT in humanmammary cell cultures. These finding are supported
by data from Zhou et al. [121] who demonstrated that a dose of
2 Gy could induce a mesenchymal phenotype in cell lines from
colorectal cancer (SW480 and SW 620), breast cancer (MCF-7 and
MDA-MB-231) and lung cancer (A549 and PC14) and that this
was associated with expression of TGF-b. The events associated
with the EMT phenotype could be reversed by inhibition of TGF-
b signalling. Similar findings have been reported for MCF-7 cells
by Zhang et al. [122] and for A549 cells by Shintani et al. [123]
who reported that induction of EMT using TGF-b reduced sensitiv-
ity to cisplatin and paclitaxel and that chronic exposure of the cells
to the drugs or radiation induced an EMT-like phenotype.
Interestingly, recent studies have demonstrated a link between
expression of the transcriptional repressors Snai 1 and 2 and resis-
tance to both radiation and the chemotherapeutic agents paclitaxel
and cisplatin in ovarian cancer cells [124,125]. Finally, exposure to
hypoxia (or TGF-b) was reported by Theys et al. [126] to induce an
EMT phenotype in certain epithelial cancer cell lines (MCF-7, A549,
NMuMG) that was reversible following reoxygenation. Expression
of the EMT-like phenotype was associated with radioresistance.
6. Clinical perspectives and conclusion
The presence of CSCs has been described in most solid tumors
and, although there are uncertainties about their exact identifica-
tion, about the plasticity of the CSC phenotype and about the ex-
tent of their resistance to treatment, such cells by definition
represent a source for treatment failure [127]. The value of the
CSC hypothesis ultimately comes from the determination of its rel-
evance for human cancer. Accumulating data demonstrate a link
between CSCs and prognosis in human cancers. In 2006, Balic
et al. [128] reported that 65–70% of disseminated tumor cells
(DTC) in bone marrow from 50 breast cancer patients, the presence
of which is a recognized independent prognostic factor, presented
Fig. 3. CSCs evade radiation-induced cell death through the activation of survival pathways. Radiotherapy has been used for the treatment of most human cancers. Despite
technical advances that allow the precise delivery of high doses of irradiation, treatment with radiation may fail to achieve long term tumor control. Treatment failure has
mainly been attributed to the presence of CSCs that survive the radiotherapy treatment and ultimately lead to tumor recurrence. The treatment resistance of CSCs is achieved
through the activation of a number of different molecular pathways that regulate cell cycle progression, DNA damage repair and cell metabolism. Additionally, several reports
have emphasized the importance of the hypoxic microenvironment in the regulation of these pathways. Furthermore, recent studies have demonstrated that treatment with
ionizing radiation results in the enrichment of CSCs in the surviving tumor mass, thus further enhancing tumor recurrence and metastasis.





Different types of MMPs have been studied seeing that they have different functions in the 
process of carcinogenesis like invasion and metastasis, tumor growth, inflammation, 
angiogenesis, apoptosis, epithelial mesenchymal transition and pre-metastatic niche formation 


















 Figure 6. Role of matrix metalloproteinases in carcinogenesis. MMPs modulate tumour 
progression in a crucial manner (Artacho-Cordón et al, 2012). 
 
 On the other hand, MMP activity is related to the level of oxidative stress in cells, so 
that the free radicals generated during irradiation of a tissue can disrupt the normal regulation 
(Klaunig & Kamendulis, 2004). It has shown an increase in invasive capacity of breast tumor 
cells after irradiation of the basal membrane due to the increased expression of MMPs 
(Paquette et al., 2007). Actived MMPs by ionizing radiation (IR) may be involved in tumour 
growth, neovascularisation and dissemination, suggesting an increased risk of metastasis in 






 MicroRNA (miRNA) is a small endogenous non-coding RNA molecule that regulates 
gene expression in transcriptional and post-transcriptional specific sequences. In 1993, Victor 
a stromelysin that is overexpressed in several tumours, after
inducing overexpression of MMP-3 in !broblasts by usingmitogens
and in"ammatory cytokines. Hence, the action of MMP-3 may be
important in chronic in"ammation secondary to breast cancer
treatment. It has been de onstrated that MMP-3 lev ls are
controlled by hypoxia [46], and that E-cadherin breakage due to
MMP-3 activity releases a fragment that promotes the invasion
capability of tumour cells [47]. MMP-3 also generates ROS through
the alternative splicing of Rac1b, and ROS-induced Rac1b stimu-
lates transcription factors such as SNAIL, which cause oxidative
damage and genomic instability [48]. It was reported that SNAIL
promotes the expression of mesenchymal proteins, such as !bro-
nectin and MMP-9 [49].
All of the above results indicate an increased expression of
MMPs by breast cancer cells that have undergone EMT, enhancing
their invasive andmetastatic potential. MMP upregulation has been
associated with various EMT processes, although the speci!c MMPs
involved appear to depend upon the nature of the EMT-inducing
agent and the model system used. MMP-3 is known to play
a crucial role in breast tumours.
Tumour growth (MMP-9, -13)
MMPs were !rst associated with tumour growth by Yu et al.,
who observed that they deregulate the balance of proliferative and
anti-proliferative signals in the tumour microenvironment. Trans-
forming growth factor-b (TGF-b), involved in a tumour-suppressor
signalling pathway, is proteolytically activated by MMP-9, which is
widely overexpressed by immune cells and inhibits cell prolifera-
tion [40,50].
MMP-13, also known as collagenase-3, has been proposed to
modulate early steps of tumour development by regulating the
activity and bioavailability of growth factors sequestered as inactive
molecules in the ECM [51]. MMP-13 is amply secreted by !broblasts
and myo!broblasts in the tumour microenvironment [52] and has
been correlated with an aggressive tumour phenotype and poor
prognosis in breast cancer patients [53,54]. For this reason, MMP-
13 may be a potential prognostic factor for metastatic risk in
breast cancer patients.
Apoptosis evasion (MMP-7)
Programmed cell death evasion has been described as a hallmark
of cancer [8]. Apoptosis is initiated by an intrinsic or mitochondrial
pathway and by an extrinsic pathway mediated by membrane
surface death receptors. Both pathways converge in caspase acti-
vation and consequent cell death. Death receptors are members of
the tumour necrosis factor (TNF) family. One of these, Fas, is acti-
vated by binding with Fas ligand (FasL) and induces a molecular
network that produces the selective and organized degradation of
sub-cellular compartments by multiple caspases. FasL is frequently
expressed by T-lymphocytes and NK cells, whereas FAS is mainly
expressed by epithelial cells. In 2002, Matrisian et al. found that
TNF-a and FasL are substrates for MMP-7, which promotes
apoptosis via proteolytic activation. This was the !rst reported link
between MMP activity and apoptosis [55,56], and was followed by
further research on the role of MMPs in apoptosis. Although MMP-
7-activated FasL was found to induce apoptosis, chronic exposure to
MMP-7 acted as a selective pressure favouring resistance to
apoptosis [57]. Subsequent !ndings con!rmed the pro-tumour
effect of chronic high MMP-7 levels [58]. Mitsiades et al. reported
that FasL was proteolytically cleaved by MMP-7 in doxorubicin-
treated cells, suppressing apoptosis and compromising the effec-
tiveness of chemotherapy [59]. In this regard, ADAM-10 has also
been implicated in apoptosis evasion due to FasL shedding [60].
Blood vessels formation (MMP-2, -9, -12)
Angiogenesis, the physiological process involving the growth of
new blood vessels from pre-existing vessels, is of crucial impor-
tance f r cancer development, not only by supplying the tumour
with nutrients (growth factors, oxygen) but also by providing
a pathway for metastatic dissemination [61]. ECM remodelling is
locally associated with angiogenesis, and both are necessary for
tumour growth and invasion [62], and MMP-derived ECM remod-
elling has been implicated in angiogenesis [63].
Angiogenesis stimulation is a further role assigned to MMPs,
especially to MMP-9, through its control over the availability of
vascular endothelial growth factor (VEGF), which is essential for
tumour neovascularisation. MMP-9 is synthesized by in"ammatory
cells, which stimulate angiogenesis by releasing sequestered VEGF,
allowing its interaction with VEGF receptors [64,65]. Angiogenesis
promotion by MMP-9 is attributable to TIMP-1-free proMMP-9,
which is solely secreted by neutrophils [66]. Vasculogenesis, i.e.,
the formation of new blood vessels from angioblasts, has also been
related to MMP-9 activity [67].
However, ECM cleavage can also exert anti-angiogenic effects,
and ECM-derived fragments with anti-angiogenic properties have
been identi!ed. Thus, the cleavage by MMPs of collagen XVIII
releases active endostatin and the cleavage of collagen IV releases
tumstatin, a potent angiogenesis suppressor. MMP-2, -9 and -12-
degraded plasminogen generates angiostatin, another anti-
angiogenic substance [68]. Some researchers have suggested that
tamoxifen, widely used in oestrogen receptor-positive breast
cancer patients, has an anti-angiogenic role through endostatin
regulation via an increase in MMP-2 and MMP-9 levels [69,70].
According to the above !ndings, the role of MMPs in angio-
genesis can vary according to the timing of their activity and the
substrate bioavailability, generating either pro-angiogenic or anti-
angiogenic signals [68].
In!ammatory response (MMP-7)
In"ammation is a physiological response to cytokine and che-
mokine production. We focus here on the main cytokines/
Figure 2. Role of matrix metalloproteinases in carcinogenesis. MMPs modulate
tumour progression in a crucial manner. MMPs are able to orchestrate invasion and
metastasis promotion, favour epithelialemesenchymal transition and tumour growth,
induce an in"ammatory response and participate in the formation of a pre-metastatic
niche. MMPs can play a dual role during apoptosis evasion and blood vessel formation.




Ambros and colleagues discovered miRNAs studing the gene of the protein lin-14 in C. 
elegans development.  Subsequent studies revealed that the 21 nucleotides transcript is 
complementary to the 3’ untranslated region (3’UTR) of lin-14 and, most interestingly, 
negatively regulates the expression of lin-14. Initially, these findings were not appreciated by 
the scientific community, because it was believed to be a rare process occurring only in C. 
elegans. However, in 2000, another such 22 nucleotides non-coding RNA named as let-7, was 
identified in C. elegans . The discovery of two miRNAs, lin-4 and let-7, in Caenorhabditis 
elegans suggested that miRNAs are important regulators of embryonic development and stem 
cell functions in mammals (Lee et al., 1993).  
 Since then, thousands of miRNAs have been identified many of which have been shown 
to play important roles in a variety of biological processes, like development, differentiation, 
apoptosis, proliferation, and cell death. It is now clear, that miRNAs together with other non-
coding RNAs (long non-coding RNAs, small nucleolar RNAs and ultraconserved regions) 
contribute to carcinogenesis. A miRNA deregulation is involved in initiation and progression 
of cancer.  They modulate the expression of their target genes by either degrading their target 
mRNA or inhibiting their translation through pairing of miRNA sequences to complementary 
bases on the target mRNA. MiRNAs can function both as oncogenes and as tumor 
suppressors and are considered as emerging potential candidates for improved cancer 
diagnosis, prognosis and therapy (Schwarzenbacher, 2013). 
 
 Biogenesis of miRNAs is a complex process. miRNAs are transcribed for the most part 
by RNA polymerase II as long primary transcripts characterized by hairpin structures (pri-
miRNA), and are processed in the nucleus by RNase III Drosha into 70–100 nucleotide long 
precursor miRNAs (pre-miRNAs) in combination with cofactors such as DGCR8, an 
evolutionarily conserved protein that interacts with prolinerich peptides through its WW 
domain (Lee et al., 2004). 
 Pre-miRNAs are then exported to the cytoplasm by the nuclear export factor Exportin 5 
and the Ran-GTP cofactor, where they are cleaved by another RNase III type enzyme, Dicer, 
to generate a ~22 nt RNA duplex. One strand of the miRNA duplex is usually selected as a 
mature miRNA, and is assembled into an RNA induced silencing complex (RISC), while the 
other strand is degraded. The RISC complex interacts with the Argonuate proteins and they 
collectively act to silence target mRNAs. The mechanism of mRNA silencing is dependent on 




degradation occurs as a consequence of endonucleolytic cleavage resulting from the proteins 
bound to RISC. However, in the case of most animals, perfect complementarity rarely exists, 
and as such the target mRNA cannot be degraded by this mechanism. Consequently, these 
imperfect miRNA/mRNA pairs are either translationally repressed or silenced independent of 
the above-mentioned mechanism. The complementarity to the messenger RNA within 
positions 1–8 of the microRNA is the most crucial parameter for regulation, and binding sites 
on the mRNA are located in most instances on the 3' untranslated region (UTR) (Figure 7) 
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Radiotherapy, through ionizing radiations, aims to cure tumors determining damages by the 
production of free radicals at various levels in the neoplastic cell.  
Cellular response to IR simultaneously activates a number of signalling pathways mediating 
the DNA damage response (DDR). Failure to repair radio-induced damages leads directly or 
indirectly to cell death, also changes ROS levels and hipoxia state. Complete recovery from 
these damages affects radiosensitivity, under physiological conditions that avoids the 
tumorgenesis, while in a clinical setting it determines tumor resistance to RT. miRNAs are 
deeply involved in the regulation of this processes. This issue promoted a high interest in the 
potential oncological applications of enhancing efficacy of RT through modification of tumor 
radiosensitivity. also useful to understand and manage treatment-related toxicity. Finally, 
miRNAs could be useful for monitoring and understanding professional and accidental 





































































miRNAs are important in the regulation of metastasis, DNA damage and hipoxia after a 
radiation therapy. Moreover, BCSC subpopulations confer resistance to this physical agent 
because of: i) the highest repair rate of DNA damage, ii) the lower levels of ROS and iii) the 
increased expression of MMPs among others. So, BCSCs that are not eliminated by radiation 
would stimulate the recurrence, invasion and metastasis processes. Since radiation enriches 
the fraction of CSCs subpopulation, this physical agent may modulate specifics miRNAs of 
these cells.  
 
 
The objective proposed in response to the previous working hypothesis is: 
 
  
 To study the difference in expression of specific miRNAs related with metastasis, 
hypoxia and DNA damage response in breast cancer stem cells after receiving radiation doses 


























































1. Cell culture: 
  
 We used the MDA-MB-231breast adenocarcinoma cell line (ATCC HTB-26 
reference), derived from a woman of 51 years old and characterized as a triple negative cell 
line (ER-/PR-/HER2-). 
  
1.1 Culture conditions: 
 
 Cell culture was performed under sterile conditions in laminar flow closet (Micro-V, 
Telstar, Spain). Cells were grown in 75 or 25 cm2 culture flasks in a CO2 incubator (CO2 
Incubator Steri-Cult, Thermo Electron Corporation, Waltham, MA, USA) at 37°C and 90% 
humidity. When reaching 80-90% confluence, cells were detached from the surface using a 
trypsin-EDTA solution and subsequently washed in culture medium with FBS to inactivate 
the trypsin by centrifugation at 1500 rpm for 5 minutes. Finally they were replanted in new 
culture flasks. 
 
 Cells were growth in DMEM (Dulbecco's Modified Eagles Medium, Sigma Chemical 
Co., St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS) (BioWhittaker, 
Lonza, Basel, Switzerland), inactivated at 56°C for 30 minutes and supplemented with 1% of 
a solution of penicillin / streptomycin (10,000 U / ml penicillin G and 10 mg / ml 
streptomycin, Sigma Chemical Co, St Louis, MO, USA). 
 
1.2  Cell freezing method: 
  
 The maintenance of cell lines over long periods of time was achieved detaching cells 
from culture flasks by trypsin-EDTA, centrifuged at 1500 rpm for 5 min in medium 
supplemented with FBS and then the cell pellet was resuspended in freezing medium at 0.5 x 
106 cells, and then introduced immediately in cryotubes. Then, cryotubes were storage in the 
freezer at -80°C for 24 h. Subsequently, for storage long time were transferred to liquid 
nitrogen at -196°C.  
Freezing Medium: Fetal bovine serum (FBS) inactivated by wet heat at 56°C for 30 min and 







1.3 Cell thawing method: 
 Cell lines stored at -80°C were thawed in moist heat at 37°C and immediately 
resuspended in saline phosphate buffered saline (PBS) and centrifuged at 1500 rpm for 5 min 
to remove residual DMSO (two washes). The pellet was resuspended in culture medium to 
finally make the seeding of the cells in culture flasks of 75 cm2. 
 
1.4 Cell count: 
 
 For cell counting, after taking off and the cells centrifuged as previously described, the 
pellet was resuspended in culture medium. For crop density, a Neubauer chamber was used. 
Cells that appeared in each quadrant of the chamber were counted, the number obtained was 
divided by four and multiplied by 10,000 and, finally, it was applied the dilution factor used 




2. Cancer stem cells isolation: 
 
 CSCs isolation was performed by detecting activity of the aldehyde dehydrogenase 
(ALDH) by flow cytometry in the breast cancer cell line MDA-MB-231. Therefore, the 
Aldefluor kit (StemCell Technologies, Vancouver, Canada) which is based in the 
quantification of the ALDH enzyme activity by metabolizing a substrate, BODIPY-
aminoacetaldehyde (BAAA), resulting in a fluorescent product, the BODIPY-aminoacetate 
(BAA). The latter is accumulated in the interior of the cell, which allows the detection and 
subsequent separation, by flow cytometry. These ALDH + cells were separated using a flow 
cytometer FACS Aria III being selected cells had an increased fluorescence for FITC 
fluorochrome. The dietilbenzaldehide (DEAB) was used as negative control, since it is a 
potent inhibitor of ALDH activity 
 
The cells were detached using trypsin-EDTA and harvested in cytometric tubes at a density 
1.000.000 cells/mL. The cells were incubated at 37 ° C for 30 min, and centrifuged. The cell 






 For the cultivation of tumor stem cells spheres medium was used: DMEM/F12 (Sigma 
Chemical Co, St Louis, MO, USA), supplemented with 1X B27 (Gibco, Big Cavin, OK, 
USA), 1 µg / ml hydrocortisone, 4ng/ml heparin, 10 µg / ml insulin, 10 ng / ml EGF, 20 ng / 
ml of FGF, and 1% of a solution of penicillin / streptomycin (10,000 U / ml penicillin G and 




3. Cell radiation: 
 
 The radiation of cells was done by the X-ray equipment Krautkramer-Foster, Smart 
Model 2006 for experimental animals and cell cultures. Cells sorted (sorter +, sorter - and 
general population) and maintained for 24 hours in sphere culture medium were radiated 
under a constant current of 4.5 mA and power of 200 kW at different doses and time (Table 










4. RNA isolation: 
 
 The total RNA was obtained one day after cells radiation. RNA extraction was 
performed using miRCURYTM RNA Isolation Kit - Cell & Plant content (EXIQON seek find 
verify). 
For this, we transfer cell suspension to an RNase-free tube and centrifuge at no more than 200 
x g for 10 minutes to pellet cells. Carefully supernatant was decanted. Then 350 µL of Lysis 
Solution was added to the pellet and cells were lyses by vortexing for 15 seconds. We added 
200 µL of 95 – 100% ethanol to the lysate and mixed by vortexing for 10 seconds. 
Moreover, we applied 400 µL of Wash Solution to the column and centrifuged for 1 minute at 
14,000 x g. Finally we placed the column into a fresh 1.7 mL Elution tube and added 50 µL of 
DOSES TIME 
2 Gy 3’ 21” 




Elution Buffer to the column and centrifuged for 2 minutes at 200 x g, followed by 1 minute 
at 14,000 x g. 
The purified RNA sample may be stored at –20°C for a few days. It is recommended that 
samples be placed at 80°C for long-term storage. 
 
4.1 Quantitation of total RNA: 
 
 For quantification of RNA, we proceeded to the reading of the absorbance at 260 and 
280 nm using a NanoDrop (NanoDrop ™ 2000/2000c Spectrophotometers, Thermo Scientific 
™). The OD260/OD280 relationship allowed us to calculate the purity of nucleic acids, 
whereas an optimal range of values between 1.8 and 2. RNA concentration was calculated 




5. Reverse transcription and qPCR to detect miRNAS 
 
 The miRCURY LNATM Universal RT microRNA PCR system was the kit used to 
detect the expression of microRNA-specific, LNATM-based system designed for sensitive and 
accurate detection of microRNA by quantitative real-time PCR using SYBR® Green.  
 
5.1 Reverse transcription: 
 
 For the reverse transcriptase reaction previously extracted RNA was used. For each 
reaction a volume of 20 µL in a nuclease free eppendorf was used. For each reaction 4µL of 
5x Reaction buffer, 2 µL enzyme mix and 4.5 µL of nuclease-free water mix was added and 
2.5 µL of RNA extracted. The reaction was mixed pipetting all the reagents.  
 
The reverse transcriptase reaction was performed in a thermocycler (DOPPIO Thermal 
Cycler, VWR). The reaction tubes were heated at 42 ° C for 60 min and then the temperature 
rose to 95 ° C for 5 min. Finally samples were kept on ice for 5 min, and the cDNA was 






5.2 Quantitative polymerase chain reaction qPCR: 
 
 Quantitative polymerase chain reaction in real time (qPCR) was carried out to validate 
the data obtained from cDNA and the primers of miRNAs selected. miRNAs selected were 
searched at the literature including as criterion hypoxia, metastasis and DDR. For this first 
experiment Hsa-mir-24 3p and Hsa-mir 210 3p were used together with an internal control 
GAPDH to normalize variations in the quality and quantity of the cDNA used. 
 For the analysis of the expression the "PCR Real-time PCR 7500 system"(Applied 
Biosystems, Inc.) system was used. The mix of 12.5 µL of SYBR Green PCR Master mix, 10 
µL of diluted cDNA and 2.5 µL of primer was used with a volume total of 25 µL. Each 
reaction was carried out in triplicate. 
The process steps for qPCR was 95 ̊C, 10 min to polymerase activation/denaturation, 40 
amplification cycles at 95 ̊C, 10 seconds and 60 ̊C 1 min. The Ct method was used to 
calculate the amplification factor as recommended by the supplier. The concentration of the 
miRNA of interest and the endogenous reference gene was determined by performing a 





























































1.  Flow cytometry based in the ALDH activity: 
 
MDA-MB-231 cells were isolated by flow cytometry based in the ALDH activity. 
 



































2. Enrichmented of  MDA-MB-231 cell line after sorting with sphere 
culture medium 
  
 To determine expression of miRNAs in breast CSCs enriched subpopulation sorted 
cells were growth into low attachment plates with sphere culture medium for 72h before 
radiation. 
As shown in Figure 8 sorted cells formed mammospheres at difference with control non-










Figure 8: a Control non-sorted population in sphere culture medium (objective 20x), b ALDH + 
sorted cells in sphere culture medium (objetive 20x) and c ALDH - sorted cells in sphere culture 




3. Expression levels of miRNAs: 
 
 miRNAs levels were measured in ALDH + CSCs (sorter positive) and non-sorted 
population (control cells)after 24 h of exposure to radiation. The ALDH negative CSC 
subpopulation was not measured in this first experiment; so only two populations were 
compared. 
 
 miRNAs examined were as follows: Hsa-mir 210 3p and Hsa-mir 24 3p together 
control GADPH. Results are shown in Table 3 and Figure 9 and 10. These data show that the 
expression of both miRNAs was different between control cells and ALDH+ CSCs with a 




mir 210 3p increased up to 91.3 folds and Hsa-mir 24 3p up to 3.1 in ALDH+ cells. After 
radiation, these levels decreased in the ALDH+ subpopulation in a dose-dependent manner.  
 
However, in non-sorted subpopulations Hsa-mir 210 3p level after treatment with 2 Gy 
decreased and this level increased after 6Gy (Figure 9). Similarly, Hsa-mir 24 3p showed the 
same behaviour in ALDH+ cells after radiation with a decreased that was dose-dependent. In 
contrast, in non-sorted cells 2 Gy increased Hsa-mir 24 3p expression level and decreased 
after treatment with 6 Gy in comparison with control non-radiated cells (Figure 10).  
 
 






















Mean SEM p-value  Mean SEM p-value 
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Figure 9: Relative miRNA 210 3p expression quantified by qRT-PCR after ionizing radiation 
in non-sorted MDA-MB 231 cells (general population) and ALDH+ cells compared with non-









Figure 10: Relative miRNA 24 3p expression quantified by qRT-PCR after ionizing radiation 
in non-sorted MDA-MB 231 cells (general population) and ALDH+ cells compared with non-











































The hypothesis proposed in this paper suggests that the response to treatment with ionizing 
radiation in breast cancer is relatedwith CSC subpopulation present in the tumor. Local 
recurrence and distant metastases, despite therapy, indicate that BCSCs are able to evade the 
effects of chemotherapy and radiotherapy and thereby repopulate the tumour following 
treatment (Ablett, 2014). Moreover, miRNAs have an important relevance in all the process 
of resistance at radiotherapy 
 
Gene analysis studies have demonstrated aberrant miRNA expression in tumors compared 
to normal tissues and that miRNAs are deregulated in an array of solid cancers as well as 
haematological malignancies. The findings of the role of miRNAs in cancer is supported by 
the fact that about 50% of miRNA genes are located in cancer associated genomic regions, or 
in fragile sites, further strengthening the evidence that miRNAs do play a crucial role in 
cancer. As a result, human miRNAs are likely to be highly useful as biomarkers, especially 
for future cancer diagnostics, and are emerging as attractive targets for disease intervention 
(Abba et al, 2014). 
 
In this paper CSCs were isolated by ALDH activity. Aldehyde dehydrogenase activity has 
been identified as a method of enriching for normal human breast stem and CSCs (Ginestier 
et al., 2007). In our experiments, we isolated and enriched MDA-MB-231 CSCs using this 
ALDH activity and culturing then in spheres medium. After three days of culturing in spheres 
medium, cells were radiated at different doses and miRNAs expression were measured 24 
hours later. 
 
We determined mir 210 3p expression since it has been identified as the most frequently 
deregulated miRNA in response to hypoxia. Hypoxia-inducible factors (HIF) are transcription 
factors that regulate various genes involved in response to hypoxia, including miR-210 
(Jacobs et al., 2014). Some works have shown that hypoxia can also promote genetic 
instability by affecting the DNA repair capability of cancer cells, due to transcriptional 
downregulation of MLH1, MSH2, BRCA-1, and RAD51 observed in hypoxic cells. Forced 
expression of miR-210 was able to suppress levels of RAD52, a key factor in homology-
dependent repair (Tessitore et al., 2013). Our results show that when non- sorted cells were 
radiated with 2 Gy, the expression of mir 210 3p decreases to 0,41 versus control although 




can be explain by the effect that the ionizing radiation has in the enrichment of “stemness” in 
cancer cell. For example, previous studies have demonstrated that ionizing radiation can 
enrich CD133+ glioma CSCs in vitro and in vivo. Moreover, these authors showed that this 
enrichment effect preferentially activation of the DNA damage checkpoint in CD133+ glioma 
CSCs compared to CD133- non-stem glioma cells (Ghisolfi et al, 2012). 
 
Surprisingly, the mir 210 3p expression increased up to 91.4 in ALDH+ cells but decreased 
in radiated cells up to 26.42 y 10.88 for 2 Gy and 6 Gy, respectively. We can interpret that 
when population is enriched in BCSCs the expression of mir 210 3p which is related with 
hypoxia and DDR is overexpressed. In fact, hypoxia may be a major component of the 
BCSCs niche, providing the BCSCs with cues for maintenance of an undifferentiated state. 
There is increasing evidence that hypoxia can affect expression of genes and pathways 
controlling stemness such as Oct4 and Notch, and that it can affect the epigenetic control of 
gene expression to promote an undifferentiated state (according to Marie-Egyptienne et al, 
2013). In contrast, when we radiate cells this level decreases significantly in a dose-dependent 
radiation manner, which means that it is killing the CSC population, although there is a 
considerable bulk of BCSCs that survives to ionizing radiation. 
 
 miR 24 3p has been identified by miRNA arrays during post-mitotic differentiation of 
hematopoietic cell lines. Moreover, overexpression of miR-24 downregulates the histone 
variant H2AX, the initial sensor protein in the double strain break (DSB) response. miR-24-
mediated suppression of H2AX renders hematopoietic cells hypersensitive to gamma-IR and 
genotoxic drugs, which might account for the reduced DNA repair capacity of terminally 
differentiated hematopoietic cells (Lal et al., 2009). Also, this miRNA has been relationed 
with ionizing radiation in a study overexpressing miR 24 3p leads to higher chromosomal 
breaks and sensitivity to ionizing radiation and other cytotoxic drugs in various cell lines 
(Metheetrairut and Slack, 2013). In our experiments, miR 24 3p expression in non sorted cells 
increased at 2 Gy up to 1.49 and decreases at 6 Gy up to 0.31 in comparison to the control 
non-radiated cells. The miR 24 3p overexpression in this population can be explain because of 
a low radiation dose could dowregulate H2AX and therefore, the DSB response. The 
downregulation observed after 6Gy treatment leads to the elimination of BCSCs in the non-





 The behaviour of miR 24 3p expression in ALDH+ cells was the same that miR 210 
3p but the difference were not significant. In not radiated ALDH+ cells there was an increase 









































































1. Our results showed that miR 210 (hypoxia) and miR 24 (DDR) are overepressed in BCSCs. 
 
2. The miR 210 expression levels were higher than those found for miR 24 in BCSCs. 
 
3. Ionizing radiation affects the expression levels of miR 210 and miR 24 both in non-sorted 
population as in ALDH+ BCSCs. 
 
4. Ionizing radiation decreases miR 210 and miR 24 expression in a dose-dependent manner 
in ALDH+ BCSCs. 
 
4. Our results suggest that the determination of these miRs could be useful markers of 


























































Abba M, Patil N, Allgayer H. MicroRNAs in the Regulation of MMPs and Metastasis. 
 Cancers (Basel). 2014 Mar 25;6(2):625-45. doi: 10.3390/cancers6020625. 
 
Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic? 
 Eur J Cancer. 2012 Sep;48(14):2104-16. doi: 10.1016/j.ejca.2012.03.019. Epub 2012 
 Apr 26. 
 
Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol. 2013;2013:290568. doi: 
 10.1155/2013/290568. Epub 2013 Feb 28. 
 
Artacho-Cordón F, Ríos-Arrabal S, Lara PC, Artacho-Cordón A, Calvente I, Núñez MI. 
 Matrix metalloproteinases: potential therapy to prevent the development of second 
 malignancies after breast radiotherapy. Surg Oncol. 2012 Sep;21(3):e143-51. doi: 
 10.1016/j.suronc.2012.06.001. Epub 2012 Jun 28. 
 
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, 
 Rich JN. Glioma stem cells promote radioresistance by preferential activation of the 
 DNA damage response. Nature. 2006 Dec 7;444(7120):756-60. Epub 2006 Oct 18. 
 
Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. Cancer stem cells as a 
 predictive factor in radiotherapy. Semin Radiat Oncol 2012;22:151–74. 
 
Bütof R, Dubrovska A, Baumann M. Clinical perspectives of cancer stem cell research in 
 radiation oncology. Radiother Oncol. 2013 Sep;108(3):388-96. 
 Doi10.1016/j.radonc.2013.06.002. Epub 2013 Jul 2. 
 
Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, 
 Buffa FM, Harris AL, Hatzigeorgiou AG, Enright AJ, Ragoussis J. Integrated analysis 
 of microRNA and mRNA expression and association with HIF binding reveals the 
 complexity of microRNA expression regulation under hypoxia. Mol Cancer. 2014 Feb 
 11;13:28. doi: 10.1186/1476-4598-13-28. 
 
Cellini F, Morganti AG, Genovesi D, Silvestris N, Valentini V. Role of microRNA in 
 response to ionizing radiations: evidences and potential impact on clinical practice for 
 radiotherapy. Molecules. 2014 Apr 24;19(4):5379-401. doi: 
 10.3390/molecules19045379. 
 
Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix 
 metalloproteinases. Clin Exp Metastasis. 2007;24(8):647-56. Epub 2007 Oct 30 
 
Chumsri S, Burger AM. Cancer stem cell targeted agents: therapeutic approaches and 
 consequences. Curr Opin Mol Ther. 2008 Aug;10(4):323-33. 
 
Chumsri and Preeti Shah. Radiation Resistance of Cancer Stem Cells as an Obstacle in 




Conley SJ, Elizabeth Gheordunescu, Pramod Kakarala, Bryan Newman, Hasan Korkaya, 
 Amber N. Heath, Shawn G. Clouthier, Max S. Wicha. Antiangiogenic agents increase 
 breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S 
 A. 2012 February 21; 109(8): 2784–2789. Published online 2012 January 23 
 doi: 10.1073/pnas.1018866109PMCID: PMC3286974 
 
Francesco Cellini, Alessio G. Morganti, Domenico Genovesi, Nicola Silvestris  and Vincenzo 
 Valentini. Role of MicroRNA in Response to Ionizing Radiations: Evidences and 
 Potential Impact on Clinical Practice for Radiotherapy. Molecules 2014, 19(4), 5379-
 5401; doi:10.3390/molecules19045379 
 
Davies KJ. The Complex Interaction of Matrix Metalloproteinases in the Migration of Cancer 
 Cells through Breast Tissue Stroma. Int J Breast Cancer. 2014;2014:839094. doi: 
 10.1155/2014/839094. Epub 2014 Mar 27. 
 
Dogini DB, Pascoal VD, Avansini SH, Vieira AS, Pereira TC, Lopes-Cendes I. The new 
 world of RNAs. Genet Mol Biol. 2014 Mar;37(1 Suppl):285-93. 
 
Edeleva EV, Shcherbata HR. Stress-induced ECM alteration modulates cellular microRNAs 
 that feedback to readjust the extracellular environment and cell behavior. Front Genet. 
 2013 Dec 31;4:305. doi: 10.3389/fgene.2013.00305. 
 
Eguiara A., Kepa Elorriagaa, Ricardo Rezolaa y Ángel García Martín. Células madre 
 tumorales: una diana terapéutica en el cáncer de mama. Rev Senol Patol Mamar. 
 2012;25(3):107-115 
 
Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A. Breast cancer stem cells: a novel 
 therapeutic target. Clin Breast Cancer. 2013 Feb;13(1):7-15. doi: 
 10.1016/j.clbc.2012.09.017. Epub 2012 Nov 3. 
 
Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor 
 therapies. J Mol Med (Berl). 2011 Feb;89(2):95-107. doi: 10.1007/s00109-010-0685-
 3. Epub 2010 Oct 2. 
 
Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. Ionizing radiation induces stemness in cancer 
 cells. PLoS One. 2012;7(8):e43628. doi: 10.1371/journal.pone.0043628. Epub 2012 
 Aug 21. 
 
Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. 
 Semin Radiat Oncol. 2009 Apr;19(2):106-11. doi: 10.1016/j.semradonc.2008.12.002. 
 
Hu H, Gatti RA. MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 
 2011 Jun;3(3):151-8. doi: 10.1093/jmcb/mjq042. Epub 2010 Dec 23. 
 
Jacobs LA, Bewicke-Copley F, Poolman MG, Pink RC, Mulcahy LA, Baker I, Beaman EM, 
 Brooks T, Caley DP, Cowling W, Currie JM, Horsburgh J, Kenehan L, Keyes E, Leite 
 D, Massa D, McDermott-Rouse A, Samuel P, Wood H, Kadhim M, Carter DR. Meta-




 associated with the radiation and hypoxia stress-responses. PLoS One. 2013 Nov 
 14;8(11):e80844. doi: 10.1371/journal.pone.0080844. eCollection 2013. 
 
Keith and Celeste Simon. Hypoxia Inducible Factors, stem cells and cancer. Published as: 
 Cell. 2007 May 4; 129(3): 465–472. 
 
Klaunig JE1, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev 
 Pharmacol Toxicol. 2004;44:239-67. 
 
Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F. Survival and 
 self-renewing capacity of breast cancer initiating cells during fractionated radiation 
 treatment. Breast Cancer Res. 2010;12(1):R13. doi: 10.1186/bcr2479. Epub 2010 Feb 
 16. 
 
Lee RC, Feinbaum RL and Ambros V (1993) The C. elegans heterochronic gene lin-4 
 encodes small RNAs with anti- sense complementarity to lin-14. Cell 75:843-54. 
 
Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ and Carthew RW (2004) 
 Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing 
 pathways. Cell 117:69-81. 
 
Li J, Shen L, Xiao XG, Fang L. MicroRNAs in breast cancer and breast cancer stem cells and 
 their potential for breast cancer therapy. Chin Med J (Engl). 2013 Jul;126(13):2556-
 63. 
 
Lu Han, Sanjun Shi, Tao Gong, Zhirong Zhang, Xun Sunn. Cancer stem cells: therapeutic 
 implications and perspectives in cancer therapy. Acta Pharmaceutica Sinica B 
 2013;3(2):65–75. 
 
Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal t
 ransition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013 Nov 
 28;341(1):63-72. doi: 10.1016/j.canlet.2012.11.019. Epub 2012 Nov 28. 
 
Metheetrairut C, Slack FJ. MicroRNAs in the ionizing radiation response and in  radiotherapy. 
 Curr Opin Genet Dev. 2013 Feb;23(1):12-9. doi:  10.1016/j.gde.2013.01.002. Epub 
 2013 Feb 28. 
 
Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness 
 properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol 
 Med. 2013 Jan;17(1):30-54. doi: 10.1111/jcmm.12004. Epub 2013 Jan 10. 
 
Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B. 
 Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the 
 cancer stem cell hypothesis. J Oncol. 2011;2011:941876. doi: 10.1155/2011/941876. Epub 
 2010 Oct 12. 
 
Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol. 2013 Aug 27;4:225. doi: 





Paquette B, Baptiste C, Therriault H, Arguin G, Plouffe B, Lemay R. In vitro irradiation of 
 basement membrane enhances the invasiveness of breast cancer cells. Br J Cancer. 
 2007 Dec 3;97(11):1505-12. Epub 2007 Nov 6. 
 
 
Phillips TM, McBride WH, Pajonk F. The response of CD24 (-/low)/CD44+ breast cancer-
 initiating cells to radiation. J Natl Cancer Inst. 2006 Dec 20;98 (24):1777-85. 
 
Takahashi RU, Miyazaki H, Ochiya T. The role of microRNAs in the regulation of cancer 
 stem cells. Front Genet. 2014 Jan 3;4:295. doi: 10.3389/fgene.2013.00295. 
 
Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Vecchiotti 
 D, Capece D, Zazzeroni F, Alesse E. MicroRNAs in the DNA Damage/Repair 
 Network and Cancer. Int J Genomics. 2014;2014:820248. doi: 10.1155/2014/820248. 
 Epub 2014 Jan 30. 
 
Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. 
 Int J Mol Sci. 2013 Jul 15;14(7):14712-23. doi: 10.3390/ijms140714712. 
 
Van Jaarsveld MT, Wouters MD, Boersma AW, Smid M, van Ijcken WF, Mathijssen RH, 
 Hoeijmakers JH, Martens JW, van Laere S, Wiemer EA, Pothof J. DNA damage 
 responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. 
 Mol Oncol. 2014 May;8(3):458-68. doi: 10.1016/j.molonc.2013.12.011. Epub 2013 
 Dec 31. 
 
Velasco-Velázquez MA, Homsi N, De La Fuente M, Pestell RG. Breast cancer stem cells. 
 Int J Biochem Cell Biol. 2012 Apr;44(4):573-7. doi: 10.1016/j.biocel.2011.12.020. 
 Epub 2012 Jan 9. 
 
Zhao L, Lu X, Cao Y. MicroRNA and signal transduction pathways in tumor radiation 
 response. Cell Signal. 2013 Jul;25(7):1625-34. doi: 10.1016/j.cellsig.2013.04.004. 
 Epub 2013 Apr 17 
